Position in CNTA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
New position
Shares Held
17,000
first reported quarter
Ownership
0.011%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in CNTA
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
52,000
PutValue
$0
PutShares
9,900
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026CSS LLC/IL holds $23,787,576 across 16 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IONS |
Ionis Pharmaceuticals Inc
|
152,289 | $12,074,994 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
29,041 | $6,998,009 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
22,580 | $1,292,027 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,820 | $1,134,842 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
6,520 | $510,320 | |
| 6 | TVTX |
Travere Therapeutics, Inc.
|
8,470 | $481,180 | |
| 7 | EXEL |
Exelixis, Inc.
|
8,709 | $473,856 | |
| 8 | INCY |
Incyte Corp
|
3,856 | $437,116 |
All Filings in CNTA
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | 17,000 | Shares | Sole | 2026-05-15 | |
| 2026-03-31 | — | 9,900 | Put | Sole | 2026-05-15 | |
| 2026-03-31 | — | 52,000 | Call | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||